Min Chen1, Xiao Lei Liu2, Yu Jie Zhang1, Yong Zhan Nie1, Kai Chun Wu1, Yong Quan Shi1. 1. State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, Shaanxi Province, China. 2. Department of Medical Insurance, Xijing Hospital, Air Force Military Medical University, Xi'an, Shaanxi Province, China.
Abstract
OBJECTIVE: We aimed to evaluate the short-term efficacy and safety of fecal microbiota transplantation (FMT) by washed preparation for moderate to severely active UC. METHODS: An open-label prospective trial was conducted in an inflammatory bowel disease (IBD) tertiary referral center from April 2016 to March 2018. Patients with moderate to severely active UC were randomly assigned to undergo FMT thrice on day 1, 3 and 5 by nasojejunal tube (NJT) or transendoscopic enteral tubing (TET). The primary end-point was a clinical response at week 2 post-FMT. The secondary end-points were clinical and endoscopic remission at week 12 post-FMT, safety and disease progression. RESULTS: Of the nine patients included, 77.8% (7/9) achieved a clinical response at week 2. And 55.6% (5/9) and 33.3% (3/9), respectively, achieved clinical remission and endoscopic remission at week 12. In two patients who had no response to FMT, one switched to anti-tumor necrosis factor-α therapy, and the other underwent a colectomy. FMT was delivered through NJT in 44.4% (4/9) of the patients, while TET was used in 55.6% (5/9). The clinical outcomes did not differ significantly based on the delivery route (P > 0.05). Adverse events, all mild and self-limiting, were observed in 33.3% (3/9) of the patients. CONCLUSIONS:FMT by washed preparation appears to be a safe and effective adjunct therapy for moderate to severely active UC during a short-term follow-up. The efficacy did not differ significantly between the NJT or TET delivery routes. Further randomized controlled studies are needed to confirm these findings.
RCT Entities:
OBJECTIVE: We aimed to evaluate the short-term efficacy and safety of fecal microbiota transplantation (FMT) by washed preparation for moderate to severely active UC. METHODS: An open-label prospective trial was conducted in an inflammatory bowel disease (IBD) tertiary referral center from April 2016 to March 2018. Patients with moderate to severely active UC were randomly assigned to undergo FMT thrice on day 1, 3 and 5 by nasojejunal tube (NJT) or transendoscopic enteral tubing (TET). The primary end-point was a clinical response at week 2 post-FMT. The secondary end-points were clinical and endoscopic remission at week 12 post-FMT, safety and disease progression. RESULTS: Of the nine patients included, 77.8% (7/9) achieved a clinical response at week 2. And 55.6% (5/9) and 33.3% (3/9), respectively, achieved clinical remission and endoscopic remission at week 12. In two patients who had no response to FMT, one switched to anti-tumor necrosis factor-α therapy, and the other underwent a colectomy. FMT was delivered through NJT in 44.4% (4/9) of the patients, while TET was used in 55.6% (5/9). The clinical outcomes did not differ significantly based on the delivery route (P > 0.05). Adverse events, all mild and self-limiting, were observed in 33.3% (3/9) of the patients. CONCLUSIONS: FMT by washed preparation appears to be a safe and effective adjunct therapy for moderate to severely active UC during a short-term follow-up. The efficacy did not differ significantly between the NJT or TET delivery routes. Further randomized controlled studies are needed to confirm these findings.
Authors: Noortje G Rossen; Susana Fuentes; Mirjam J van der Spek; Jan G Tijssen; Jorn H A Hartman; Ann Duflou; Mark Löwenberg; Gijs R van den Brink; Elisabeth M H Mathus-Vliegen; Willem M de Vos; Erwin G Zoetendal; Geert R D'Haens; Cyriel Y Ponsioen Journal: Gastroenterology Date: 2015-03-30 Impact factor: 22.682
Authors: Christina M Surawicz; Lawrence J Brandt; David G Binion; Ashwin N Ananthakrishnan; Scott R Curry; Peter H Gilligan; Lynne V McFarland; Mark Mellow; Brian S Zuckerbraun Journal: Am J Gastroenterol Date: 2013-02-26 Impact factor: 10.864
Authors: Axel Dignass; Rami Eliakim; Fernando Magro; Christian Maaser; Yehuda Chowers; Karel Geboes; Gerassimos Mantzaris; Walter Reinisch; Jean-Frederic Colombel; Severine Vermeire; Simon Travis; James O Lindsay; Gert Van Assche Journal: J Crohns Colitis Date: 2012-10-03 Impact factor: 9.071
Authors: Paul Moayyedi; Michael G Surette; Peter T Kim; Josie Libertucci; Melanie Wolfe; Catherine Onischi; David Armstrong; John K Marshall; Zain Kassam; Walter Reinisch; Christine H Lee Journal: Gastroenterology Date: 2015-04-07 Impact factor: 22.682
Authors: Dan Turner; Catharine M Walsh; A Hillary Steinhart; Anne M Griffiths Journal: Clin Gastroenterol Hepatol Date: 2006-12-04 Impact factor: 11.382
Authors: Els van Nood; Anne Vrieze; Max Nieuwdorp; Susana Fuentes; Erwin G Zoetendal; Willem M de Vos; Caroline E Visser; Ed J Kuijper; Joep F W M Bartelsman; Jan G P Tijssen; Peter Speelman; Marcel G W Dijkgraaf; Josbert J Keller Journal: N Engl J Med Date: 2013-01-16 Impact factor: 91.245
Authors: Byron P Vaughn; Tommi Vatanen; Jessica R Allegretti; Aiping Bai; Ramnik J Xavier; Joshua Korzenik; Dirk Gevers; Amanda Ting; Simon C Robson; Alan C Moss Journal: Inflamm Bowel Dis Date: 2016-09 Impact factor: 5.325
Authors: Sieglinde Angelberger; Walter Reinisch; Athanasios Makristathis; Cornelia Lichtenberger; Clemens Dejaco; Pavol Papay; Gottfried Novacek; Michael Trauner; Alexander Loy; David Berry Journal: Am J Gastroenterol Date: 2013-09-24 Impact factor: 10.864
Authors: Valentin Mocanu; Sabitha Rajaruban; Jerry Dang; Janice Y Kung; Edward C Deehan; Karen L Madsen Journal: J Clin Med Date: 2021-03-01 Impact factor: 4.241